related disorders.

Almatica is the company’s US branded arm focused on CNS product development. Gralise® is the company’s lead product, a once daily form of gabapentin used to treat pain after shingles, or postherpetic neuralgia (PHN). In addition, the company is developing a pipeline of CNS targeted therapies, with the lead product expected to launch in 2021. Almatica Pharma currently markets a portfolio of US brand name pharmaceutical products covering a wide range of therapeutic areas including: psychiatry, pain management, anti-infectives and cardiovascular related disorders. Almatica also provides patient cost savings programs for several of its products.

Almatica is actively pursuing the expansion of its US product portfolio through the development of its own product pipeline and through the in-licensing and acquisition of products that are either marketed or in late stage development. The growth of the company’s business is supported by a broad range of in-house commercial, manufacturing and R&D related capabilities.

Almatica Pharma LLC is a US subsidiary of Alvogen. The parent company Alvogen, is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the counter (OTC) and biosimilar products for patients around the world. The company has commercial operations in 20 countries with 1,700 employees and operates four manufacturing and development hubs in the US, Korea and Taiwan.